INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 412m ago
HOUSE PTR12m ago
SEC 13F12m ago
ROBINHOOD CHAIN11m ago
SEC FORM 4/Open-market purchaseVerified data

George Jeffrey P. bought LENZ

Director · LENZ Therapeutics, Inc. · Common Stock

Side
BUY
Value
$50K
Shares
5,592
Price
$8.92
Executed
Mar 27, 2026
Disclosed
Mar 30, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Mar 27 executedMar 30, 2026 disclosed

LENZ · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
51/ 100 · NOTABLE
Methodology →
  • Transaction type+20 / 20

    Open-market purchase

  • Relative size+13 / 25

    $50K reported value · new position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+10 / 15

    2 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · LENZ

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    57
    SB
    Schimmelpennink Evert B.Director, President, CEO and Secretary
    LENZLENZ Therapeutics, Inc.
    Open-market purchase
    		BUY$251K
    28.1K sh
    		Mar 27, 2026Mar 30, 2026
    traded Mar 27, 2026
    		+3dSEC FORM 4

    Evidence

    50
    CR
    Chevallard Daniel R.Chief Financial Officer
    LENZLENZ Therapeutics, Inc.
    Open-market purchase
    		BUY$64K
    7,500 sh
    		Mar 27, 2026Mar 30, 2026
    traded Mar 27, 2026
    		+3dSEC FORM 4

    Evidence

    5
    OS
    Olsson ShawnChief Commercial Officer
    LENZLENZ Therapeutics, Inc.
    Grant or award
    		A—
    14.0K sh
    		Jan 2, 2026Jan 6, 2026
    traded Jan 2, 2026
    		+4dSEC FORM 4

    Evidence

    9
    OM
    Odrich MarcChief Medical Officer
    LENZLENZ Therapeutics, Inc.
    Grant or award
    		A—
    84.2K sh
    		Jan 2, 2026Jan 6, 2026
    traded Jan 2, 2026
    		+4dSEC FORM 4

    Evidence

    5
    OS
    Olsson ShawnChief Commercial Officer
    LENZLENZ Therapeutics, Inc.
    Grant or award
    		A—
    84.2K sh
    		Jan 2, 2026Jan 6, 2026
    traded Jan 2, 2026
    		+4dSEC FORM 4

    Evidence

    9
    OM
    Odrich MarcChief Medical Officer
    LENZLENZ Therapeutics, Inc.
    Grant or award
    		A—
    14.0K sh
    		Jan 2, 2026Jan 6, 2026
    traded Jan 2, 2026
    		+4dSEC FORM 4

    Evidence

    20
    OS
    Olsson ShawnChief Commercial Officer
    LENZLENZ Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$153K
    5,788 sh
    		Nov 17, 2025Nov 19, 2025
    traded Nov 17, 2025
    		+2dSEC FORM 4

    Evidence

    16
    OS
    Olsson ShawnChief Commercial Officer
    LENZLENZ Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$108K
    4,212 sh
    		Nov 17, 2025Nov 19, 2025
    traded Nov 17, 2025
    		+2dSEC FORM 4

    Evidence

    7
    OS
    Olsson ShawnChief Commercial Officer
    LENZLENZ Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    10.0K sh
    		Nov 17, 2025Nov 19, 2025
    traded Nov 17, 2025
    		+2dSEC FORM 4

    Evidence

    11
    OS
    Olsson ShawnChief Commercial Officer
    LENZLENZ Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$21K
    10.0K sh
    		Nov 17, 2025Nov 19, 2025
    traded Nov 17, 2025
    		+2dSEC FORM 4

    Evidence

    49
    MW
    Mccollum James WDirector
    LENZLENZ Therapeutics, Inc.
    Open-market purchase
    		BUY$239K
    10.5K sh
    		Nov 7, 2025Nov 10, 2025
    traded Nov 7, 2025
    		+3dSEC FORM 4

    Evidence

    46
    CR
    Chevallard Daniel R.Chief Financial Officer
    LENZLENZ Therapeutics, Inc.
    Open-market purchase
    		BUY$50K
    2,178 sh
    		Nov 7, 2025Nov 7, 2025
    traded Nov 7, 2025
    		+0dSEC FORM 4

    Evidence

    34
    CR
    Chevallard Daniel R.Chief Financial Officer
    LENZLENZ Therapeutics, Inc.
    Open-market purchase
    		BUY$454
    20 sh
    		Nov 7, 2025Nov 7, 2025
    traded Nov 7, 2025
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001796789-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 27, 2026
    Published
    Mar 30, 2026
    Ingested by INSIDER
    Nov 5, 04:08 UTC
    Last re-read
    Nov 5, 04:08 UTC

    Extracted facts

    Filer
    George Jeffrey P.
    Role
    Director
    Transaction
    Open-market purchaseAs filed: “P”
    Asset
    LENZ Therapeutics, Inc.
    Ticker
    LENZ
    Shares
    5,592
    Price per share
    $8.92
    Value
    $49,890
    Execution date (reported)
    Mar 27, 2026
    Owned after transaction
    5,592 shares
    Days from execution to publication
    3

    Calculation

    Value = shares × reported price per share

    • Shares: 5,592
    • Price: $8.9217

    = $49,890

    What this establishes

    George Jeffrey P. filed this Form 4 reporting a open-market purchase of LENZ on Mar 27, 2026. It became public on Mar 30, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    George Jeffrey P.cik:0001796789
    Issuer
    LENZ Therapeutics, Inc.cik:0001815776

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.